The need for precise dose information of sodium selenite in the SIC study and rectification of GPx-3 plasma concentration [11]

Critical Care Medicine

Volumn 36, Issue 2, 2008, Pages 656-657

  Forceville, Xavier ^a  

^a CENTRE HOSPITALIER DE MEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 3; SELENIUM; SODIUM SELENITE; UNCLASSIFIED DRUG;

CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; INTENSIVE CARE; LETTER; MEDICAL LITERATURE; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 38549134376     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCM.0B013E318162B8DE     Document Type: Letter

References (2)

1. Angstwurm MW, Engelmann L, Zimmermann T, et al: Selenium in Intensive Care (SIC): Results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007; 35:118-126
2. Forceville X, Vitoux D, Gauzit R, et al: Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients. Crit Care Med 1998; 26:1536-1544